In a significant move at the larger end of the biopharma world, AstraZeneca’s global VP of cardiovascular, renal and metabolism made the move to Novo Nordisk to head up its biopharm unit.
As the stream of executives flowing from large pharma companies to smaller biotechs builds into a torrent, another month has passed with a number of significant switches. Notably, two former Genentech employees, responsible for work on some of its bestselling...
Ambition, hard work and a focus on quality has made Celltrion the ‘pioneers of the mAb biosimilar industry,’ the firm told Biopharma-Reporter during a tour of its biomanufacturing site in Songdo, Korea.
Senior Scientist at Pfizer? Head of Upstream Development at GSK? How about working at B-MS’s expanding facility in Massachusetts? Time to dust off those CVs and check out the latest biopharma jobs.
Former Secretary of State and First Lady Hillary Clinton popped in for a long interview during one of the keynote luncheons to discuss all sorts of different topics with a BIO executive. The luncheon nicely complimented the international theme of the...
A government funded bioprocessing institute is helping to drive biopharma investment and retrain workers in Ireland, and Biopharma-Reporter.com visited to find out what happens in this "flight simulator for biopharma manufacturing."
Outdated technology is one of the greatest challenges in creating next-generation biodrugs, says Jonathan Robinson, who is leading the development of a £38m ($63m) national biomanufacturing hub in the UK.
Lab rats are not the only animals to play a role in bologics development as Biopharma-Reporter.com discovered when it donned its wellington boots and took a wonder down to the pharm...
Last year Octapharma filed the world’s first ‘truly human’ recombinant Factor VIII clotting protein for EMA review and invited BioPharma-Reporter.com to visit the Swedish site where it makes the haemophilia treatment using HEK cells.
With more and more biopharmaceutical firms developing therapeutic antibodies public knowledge of these powerful molecules is increasing, which is good news given how badly they've been portrayed in films so far.
Aesica's new Technical Director talks CMO flexibility and Catalent appoints new delivery unit head - welcome to Outsourcing-Pharma's People on the Move.
BMS have appointed a new director and ex Shire-CEO joins Questcor - yes, you've guessed it, it's in-Pharmatechnologist.com's weekly pharma people round-up.
In-Pharmatechnologist.com presents its latest round-up of the movers and shakers in the world of pharmaceuticals, including news from the MHRA, Achillion and Halozyme.
Outsourcing-Pharma.com presents its latest round-up of the movers and shakers in the pharma service industry, including news from Theorem and Symbiosis.
In-Pharmatechnologist.com presents its latest round-up of the movers and shakers in the world of pharmaceuticals, including news from Novartis, Teva and the EMA.
Outsourcing-Pharma.com presents its latest round-up of the movers and shakers in the pharma service industry, including news from Catalent, Hospira and Eisai.
Outsourcing-Pharma.com presents its latest round-up of the movers and shakers in the pharma service industry, including news from Lonza and SynteractHCR.
In-PharmaTechnologist.com presents its latest round-up of the movers and shakers in the world of pharmaceuticals, including news from Glide, BASF and Pall.
Outsourcing-Pharma.com presents its latest round-up of the movers and shakers in the pharma service industry, including news from Catalent, Dow and Agere Pharmaceuticals.
in-Pharmatechnologist.com presents a roundup of news in the fine chemicals sector, beginning with Johnson Matthey which has started a review of its active pharmaceutical ingredient (API) business after competition in the UK impacted its third quarter...
Outsourcing-Pharma.com presents its latest round-up of the movers and shakers in the pharma service industry, including news from Recipharm, Aesica and SMS Oncology.
in-PharmaTechnologist.com presents its weekly round-up of the latest chops and changes in the pharmaceutical development and manufacturing industry, including news from Pfizer, Cresset, and Avantor.
in-PharmaTechnologist presents its weekly round-up of the latest climbers on the pharmaceutical career ladder, including news from Novasep, BioTime and Syndax.
in-PharmaTechnologist brings you its weekly round-up of the latest chops and changes on the pharmaceutical career ladder, including news from J&J, Sirona, and Ova Science.
in-PharmaTechnologist presents its weekly round-up of the latest appointments in the pharmaceutical industry, including news from Silence Therapeutics, Accorda, and Hospira.
Outsourcing-Pharma presents its weekly round-up of the latest changes on the pharmaceutical career ladder, including news from Patheon, Wolfe Laboratories, and Premier Research.
in-PharmaTechnologist presents its weekly round-up of the latest new faces at pharmas and biotechs, including news from Dicerna, Auxilium and Essentialis.
Outsourcing-Pharma presents its weekly round-up of the latest movers and shakers in the pharmaceutical industry, including news from Inviragen, Auxilium, and Icon Biosciences.
in-PharmaTechnologist presents its round-up of the latest career moves within the world of pharmaceuticals, including news from AstraZeneca, Apricus, and BioTime.
in-PharmaTechnologist presents its weekly line-up of the latest appointments in the pharmaceutical industry, including news from Genesis, Acino and Pharmalink AB.
Outsourcing-Pharma presents its weekly round-up of the latest happenings in the world of pharmaceutical employment, including news from Genzyme, Catalent and Futura.
Outsourcing-Pharma presents its round-up of the latest appointments within the pharmaceutical industry, with news from Sucampo, Tranzyme, and Next Pharma.
in-PharmaTechnologist presents its latest round-up of the movers and shakers within the pharmaceutical industry, including appointments from AAPS, SurModics, Diamedica, and Sirona Biochem.
By Lee S. Scheible, RPh., CA-AM and Jeffrey S Kasher, PhD
Sponsors need to abandon the ‘single trial, random, tactical sourcing approach’ in favour of a model flexible enough for a variety of study designs and research needs according to Eli Lilly experts Lee Scheible and Jeffrey S Kasher in this exclusive guest...
